Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Suven Life Sciences Breathes New Life Into Drug Discovery Plans
Details : SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.
Product Name : SUVN-502
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2023
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.
Product Name : SUVN-502
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable